UK MHRA approves Incyte's Zynyz for advanced anal cancer as NICE backs NHS access
The UK MHRA has authorised Incyte's Zynyz with carboplatin and paclitaxel for advanced anal cancer, accompanied by a positive NICE access recommendation and Phase III evidence of improved median overall survival.
The UK Medicines and Healthcare products Regulatory Agency announced on 11 November 2026 that it had authorised retifanlimab (Zynyz) in combination with carboplatin and paclitaxel for adults with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal, establishing a new UK treatment indication for Incyte's immunotherapy.
NICE also supported access for eligible patients in England and Wales, with initial Cancer Drugs Fund availability and subsequent routine commissioning described in contemporary reporting, while the pivotal POD1UM-303 trial reported median overall survival of 32.8 months with the retifanlimab combination compared with 22.2 months for chemotherapy plus placebo; the UK decision is distinct from earlier approvals in other jurisdictions.
Field | Content |
Article Type | Approvals |
Company | Incyte |
Product Brand Name | Zynyz |
Active Ingredient | Retifanlimab |
Regulatory Authority | UK Medicines and Healthcare products Regulatory Agency |
Regulatory Authority Abbreviation | MHRA |
Announcement Date | 11 November 2026 |
Regulatory Decision | UK marketing authorisation for an advanced anal cancer indication |
Approved Regimen | Retifanlimab plus carboplatin and paclitaxel |
Immunotherapy Component | Retifanlimab |
Chemotherapy Component One | Carboplatin |
Chemotherapy Component Two | Paclitaxel |
Therapeutic Area | Oncology |
Cancer Type | Squamous cell carcinoma of the anal canal |
Approved Population | Adults with unresectable locally recurrent or metastatic disease |
Disease Stage | Unresectable locally recurrent or metastatic |
Treatment Setting | Advanced anal cancer |
Health Technology Assessment Body | National Institute for Health and Care Excellence |
HTA Body Abbreviation | NICE |
NICE Outcome | Positive NHS access recommendation |
NICE Geographic Scope | England and Wales |
Initial Access Route | Cancer Drugs Fund according to contemporary reporting |
Routine Commissioning Timeline | Expected within 90 days according to contemporary reporting |
Supporting Clinical Trial | POD1UM-303 |
Clinical Trial Phase | Phase III |
Key Efficacy Endpoint | Overall survival |
Median Overall Survival With Retifanlimab Combination | 32.8 months |
Median Overall Survival With Chemotherapy and Placebo | 22.2 months |
Reported Median Overall Survival Difference | 10.6 months |
Prior International Regulatory Context | Earlier US and EU approvals |
Separate UK Indication | Merkel cell carcinoma |
What Happened | The MHRA authorised a new advanced anal cancer indication for Zynyz with chemotherapy and NICE supported patient access. |
Why It Matters | The decision creates an additional immunotherapy-based treatment option for patients with difficult-to-treat advanced anal cancer. |
Clinical Significance | The pivotal trial reported longer median overall survival with the retifanlimab combination than with chemotherapy and placebo. |
Regulatory Significance | Represents a UK indication approval distinct from previous international authorisations. |
Access Significance | The NICE recommendation supports a pathway toward NHS availability for eligible patients. |
Key Takeaway | Zynyz plus carboplatin and paclitaxel has gained UK approval for advanced anal cancer alongside a positive NICE access recommendation. |
What to Watch | NHS implementation, patient access, real-world treatment outcomes and longer-term survival and safety evidence. |
Primary Source | UK Medicines and Healthcare products Regulatory Agency |
Primary Source URL | https://www.gov.uk/government/news/mhra-approves-retifanlimab-zynyz-for-the-treatment-of-advanced-anal-cancer |
Submitted Source | pharmaphorum |
Submitted Source URL | https://pharmaphorum.com/news/nhs-use-incytes-anal-cancer-drug-zynyz-backed-nice |
Relevant Date | 11 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare